We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Fluidic Sciences Relaunches Microfluidic Diffusional Sizing—Refining Protein-Protein Interaction Analysis

The Fluidity One-M instrument with the inbuilt Microfluidic Diffusional Sizing (MDS) technology.
Credit: Fluidic Sciences Ltd.
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 2 minutes

Fluidic Sciences Ltd., announces its official launch as a company, and the commercial relaunch of the acquired Fluidity One-M instrument for measuring protein-protein interactions in solution—leveraging Microfluidic Diffusional Sizing (MDS) technology. The entry of Fluidic Sciences into the market gives scientists a new option for enhanced protein biophysical characterization—advancing biopharmaceutical R&D in areas such as membrane protein characterization, vaccine responses, monoclonal therapeutic antibodies and targeted protein degradation.


MDS technology stands out as a robust and easy method for characterizing protein interactions in solution. It does not require immobilization or purification of the samples like traditional methods. One can use MDS to quantify protein-protein interactions even in mixtures such as serum, cell lysates, or proteins in nanodiscs, making it possible to study protein native structures and activities.

Want more breaking news?

Subscribe to Technology Networks’ daily newsletter, delivering breaking science news straight to your inbox every day.

Subscribe for FREE

Another hallmark benefit of MDS lies in its ability to simultaneously determine protein molecular size, binding affinity, and concentration of binding partners, which is suitable for analyzing unknown antibody concentration in serum. MDS can also measure stoichiometry and reveal the mechanism of protein interactions.


The Fluidity One-M instrument, equipped with in-built MDS technology, has been extensively utilized in many publications and projects. These cover different applications, including profiling the immune response to SARS-CoV-2 variants and studying the aggregation of the α-Synuclein protein associated with Parkinson’s disease. Using MDS to study the mechanism of action of anti-Aβ antibodies related to Alzheimer’s disease, Professor Sara Linse, Lund University, commented, “MDS allowed us to obtain unique information that helped us elucidate, for the first time, the way antibody therapeutics bind to different forms of their targets.”


MDS and the Fluidity One-M instrument were originally developed by Fluidic Analytics Ltd., which entered administration in November 2023, ceasing trading later in the month. Fluidic Sciences Ltd., a dynamic team of forward-thinking microfluidic experts, has acquired the Fluidity One-M instrument and associated assets from the administrators.


Fluidic Analytics’ administration was unfortunate, but the core technology is excellent and we believe we can add to its capabilities. There are already 30 to 40 international customers who find the instrumentation very useful, so we can build on a sound base.” said David Newble, Board Member at Fluidic Sciences.


After extensive efforts to revamp and reform the acquired assets, Fluidic Sciences will simultaneously begin delivery of One-M consumables to existing customers as well as offer Fluidity One-M instruments to new customers seeking cutting-edge protein-protein interaction analysis solutions.


Mark Gilligan, Board Member at Fluidic Sciences added, “The previous team at Fluidic Analytics did a great job of developing a unique and powerful technology. Thanks to everyone who has been involved in the refounding activity, this is now ready to be a truly successful global business. It has been a large effort and we look forward to being able to serve the biopharmaceutical industry going forwards.”


To motivate impactful research, the company is also launching an early adopter program, presenting introductory pricing throughout 2024.